Search

everythinglearnresearchcommunity

for

Search:↓

Scientists developed a new way to study mutations in a skin condition using blood cells, which may help diagnose and treat the disease.

EDA is vital for bone and cartilage formation and could help treat skeletal disorders.

I cannot summarize the document because it cannot be parsed.

The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.

SSAT is a key enzyme affecting cell growth and metabolism, with potential but risky use in disease treatment.

Dihydrotestosterone can be made from dehydroepiandrosterone in skin cells without needing testosterone.

The DNMT3B -579G>T polymorphism may increase the risk of colorectal cancer.

Delta1 is crucial for controlling skin cell growth and preventing tumors in mice.

UBC13 and UBC22 enzymes are important for plant growth and development in Arabidopsis thaliana.

There is no cure for myotonic dystrophy type 1, so treatment focuses on managing symptoms and complications.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Squaric acid dibutylester effectively treats alopecia areata.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

Future research on ectodysplasin should explore its role in diseases, stem cells, and evolution, and continue developing treatments for genetic disorders like hypohidrotic ectodermal dysplasia.

A new mouse mutation causes skin and hair defects due to a gene change.

Trichothiodystrophy hair is structurally abnormal with protein and organization issues.

Minoxidil treatment improves heart defects in a DiGeorge syndrome model.

Tay syndrome is a unique genetic disorder causing skin, hair, and developmental issues.

DHT inhibition may increase spinal bone growth in ankylosing spondylitis.

Biotin supplements improved skin and hair problems in a girl with biotinidase deficiency.

The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.

EBF1 controls hair type and length.

ETS2 drives cancer progression in squamous cell carcinoma and is linked to poor patient outcomes.

Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.

AHST shows promise for treating type 1 diabetes but needs more research before widespread use.

XEDAR deficiency prevents muscle degeneration in EDA-A2 transgenic mice.

INT effectively shows enzyme activity and protein groups in wool and hair follicles.